2. Metabolic Disease

Metabolic Disease (代謝)

Metabolic Disease

関連製品

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-173267
    CES2A-IN-2 99.16%
    CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC50 of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice.
    CES2A-IN-2
  • HY-17379R
    Atorvastatin hemicalcium salt (Standard) 134523-03-8 99.65%
    Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium salt (Standard)
  • HY-176518
    ssPalmE-P4-C2 2247153-41-7 98.81%
    ssPalmE-P4-C2 is a SS-cleavable and pH-sensitive lipid-like material (ssPalm) with a vitamin E‑scaffold. ssPalmE-P4-C2 improves gene knockdown activity against FVII with an ED50 of 0.5 mg/kg. ssPalmE-P4-C2 can be used to synthesize lipid nanoparticles (LNPs) for delivering siRNA to the hepatocyte. ssPalmE-P4-C2 can be used for the RNA therapies for dyslipidemia, hepatitis B/C infections and transthyretin amyloidosis research.
    ssPalmE-P4-C2
  • HY-177073
    Cleminorexton 2980518-93-0 98%
    Cleminorexton is an orally active orexin-2 receptor (OX2R) agonist with a pEC50 between 9 and 10.4. Cleminorexton can be used for narcolepsy and other conditions associated with orexin deficiency and/or excessive sleepiness.
    Cleminorexton
  • HY-177829
    Liposomal Vitamin C
    Liposomal Vitamin C is a specialized delivery system that encapsulates vitamin C within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of vitamin C. Vitamin C (L-ascorbic acid) is a water-soluble vit
    Liposomal Vitamin C
  • HY-179572
    STA-013 99.18%
    STA-013 is a EphB tyrosine kinase inhibitor. STA-013 shows promising potency against EphB1 (IC50 = 0.69 µM), EphB2 (IC50 = 1.73 µM), and EphB4 (IC50 = 1.02 µM) tyrosine kinases. STA-013 results a inhibition of the EphB phosphorylated signal, coupled with increased p-AKT/AKT signaling, to suggest insulin signaling activation. STA-013 inhibits EphB tyrosine kinase by enhancing insulin receptor beta (IRβ) signaling, and decreasing TGF-β levels in the heart. STA-013 can be used for the study of type 2 diabetes and cardiac complications (diabetic cardiomyopathy).
    STA-013
  • HY-179581
    SLC6A19-IN-4 2962069-39-0 99.55%
    SLC6A19-IN-4 is an allosteric-competitive and orally active B0AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B0AT1 with IC50 values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B0AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6-family transporters research.
    SLC6A19-IN-4
  • HY-181126
    G194-0712 1029737-28-7 99.82%
    G194-0712 is a selective histone deacetylase 5 (HDAC5) activator with an EC50 of 7.96 μM and a Kd of 2.53 μM. G194-0712 restores ACTN4-K417 deacetylation and nuclear import, and increases CSTA expression. G194-0712 accelerates wound closure in chronic wound models, reducing wound area and epithelial gap. G194-0712 can be used for the research of chronic skin wounds, such as diabetic wounds, ischemic wounds, radiation injury wounds.
    G194-0712
  • HY-183032
    ABC transporter modulator-1 3093661-22-1
    ABC transporter modulator-1 (Compound I-5) is an ABC transporter expression enhancer. ABCC6 modulator-1 upregulates the expression of wild-type ABCC6, wild-type ABCB4, and ABCA4P1380L mutant, with an EC50 of <1 μM for all.
    ABC transporter modulator-1
  • HY-183033
    ABC transporter modulator-2 3093663-15-8
    ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator. ABC transporter modulator-2 upregulates the expression of wild-type ABCC6 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCB4 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCD2 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of the ABCA4P1380L mutant with an EC50 of <1 μM. ABC transporter modulator-2 can be used in the research of diseases associated with ABC transporter dysfunction.
    ABC transporter modulator-2
  • HY-183034
    ABC transporter modulator-3 3093661-88-9
    ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.
    ABC transporter modulator-3
  • HY-185107
    CTR/AMYR modulator-2 3108095-52-6 98%
    CTR/AMYR modulator-2 (Example 107) is a receptor 3 for pancreatic amyloid peptide (bAMY3R) agonist, and its EC50 for stimulating cAMP production in cells is ＜500 nM. CTR/AMYR modulator-2 is also a receptor for calcitonin (bCTR) agonist, with its EC50 being ＜5000 nM. CTR/AMYR modulator-2 can be used for research on type 2 diabetes and obesity.
    CTR/AMYR modulator-2
  • HY-186178
    CD38-IN-6 2766686-04-6 99.96%
    CD38-IN-6 is an orally active CD38 inhibitor. CD38-IN-6 regulates NAD+ metabolite levels in the liver of aged obese mice by increasing NAD+ and NMN levels, and decreasing NAM and ADPR levels. CD38-IN-6 alleviates inflammatory responses in mice. CD38-IN-6 can be used for research related to obesity and inflammation.
    CD38-IN-6
  • HY-30004R
    1-Aminocyclopropane-1-carboxylic acid (Standard) 22059-21-8
    1-Aminocyclopropane-1-carboxylic acid (Standard) is the analytical standard of 1-Aminocyclopropane-1-carboxylic acid. This product is intended for research and analytical applications. 1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity..
    1-Aminocyclopropane-1-carboxylic acid (Standard)
  • HY-32349S
    Ercalcidiol-d3

    25-Hydroxy Vitamin D2-d3

    		1217467-39-4 99.86%
    Ercalcidiol-d3 is the deuterium labeled Ercalcidiol. Ercalcidiol is a metabolite of Vitamins D2. Ercalcidiol can be used as an indicator of vitamins D status.
    Ercalcidiol-d3
  • HY-41982R
    D-Glucuronic acid lactone (Standard) 32449-92-6 99.96%
    D-Glucuronic acid lactone (Standard) is the analytical standard of D-Glucuronic acid lactone. This product is intended for research and analytical applications. D-Glucuronic acid lactone is an endogenous metabolite.
    D-Glucuronic acid lactone (Standard)
  • HY-B0218S
    Orlistat-d3 1356930-46-5 99.9%
    Orlistat-d3 is a deuterated labeled Orlistat. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity.?Anti-atherosclerotic?effect.
    Orlistat-d3
  • HY-B0235R
    Trichlormethiazide (Standard) 133-67-5 98.11%
    Trichlormethiazide (Standard) is the analytical standard of Trichlormethiazide. This product is intended for research and analytical applications. Trichlormethiazide is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
    Trichlormethiazide (Standard)
  • HY-B0254S
    Glipizide-d11 1189426-07-0
    Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans.
    Glipizide-d11
  • HY-B0287R
    Clofibrate (Standard) 637-07-0 98.46%
    Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.
    Clofibrate (Standard)
製品番号 製品名 / Synonyms Application Reactivity